← Back to Home

Opening Dozens of Pathways at Once With Light: Accelerating the Chemical Search for Nucleoside Antiviral Drugs

The research team replaced the time-consuming, separate construction of individual nucleoside molecules with an approach that starts from the same scalable core. The first batch of more than 70 compounds has shown anti-HIV signals, but a lengthy screening process remains before hits from cell-based assays can become usable drugs.

By SURL BioNews

When confronting emerging viruses, the scarcest resource is often not just good ideas, but chemical methods capable of rapidly delivering large numbers of candidate molecules. Researchers at Simon Fraser University and Merck have introduced a light-driven synthesis platform that allows multiple nucleoside analogues to be derived from a shared molecular core, eliminating the need to devise a lengthy new route for every candidate. The findings have been published in *Science*.

Nucleoside analogues mimic the basic building blocks of DNA or RNA. If mistakenly incorporated by a virus’s replication machinery, they may disrupt the synthesis of genetic material, making them a longstanding source of drugs for HIV, hepatitis, and other viruses. The difficulty is that combining a sugar-like core with different nucleobases often requires complex stereochemical control, and even a slight modification to a candidate structure may require an entirely different synthesis procedure.

The new method first produces a universal intermediate at scale and then attaches different nucleobases using a photoredox coupling reaction. The paper’s abstract indicates that the platform encompasses not only carbon-linked and nitrogen-linked nucleoside analogues, but can also be extended to categories including 4′-thio, 4′-imino, and ProTide prodrugs. In other words, the researchers have changed more than a single step: they have established a manufacturing framework for exploring a larger chemical space from a common starting point.

Using this approach, the team created an initial library of more than 70 compounds, most of them new molecules. According to results released by Simon Fraser University, HIV screening conducted by Ralph Pantophlet’s laboratory identified three compounds with activity comparable to that of approved HIV therapies. Robert Britton also estimated that the approach could generate molecular libraries 10 to 100 times larger than those produced through conventional processes within a matter of weeks. However, the publicly available information has not yet provided complete potency values, comparator drugs, testing conditions, or the scope of replicate validation, so “comparable” should not be interpreted directly as equivalent clinical efficacy.

The immediate value of this work is that it gives the early stages of drug discovery faster access to structural diversity. Researchers can simultaneously test which modifications improve antiviral activity, evade drug-resistance mutations, or improve a molecule’s performance after entering cells. Because the common intermediate can be produced at scale, the approach may also reduce the burden of repeatedly rebuilding synthesis routes as hits advance into subsequent medicinal chemistry optimization.

However, hits from cell-based screening still face numerous hurdles before becoming drug candidates, including toxicity to host cells, effectiveness against different viral strains and drug-resistant strains, metabolism and distribution in the body, and the ability to maintain effective concentrations at safe doses. This study demonstrates a broader, faster chemical entry point—not three new anti-HIV drugs already approaching the clinic. Whether it can genuinely shorten development timelines during the next viral threat will depend on whether subsequent biological validation and process translation can keep pace.

References

  1. Simon Fraser University
  2. PubMed
  3. Simon Fraser University News
  4. The Britton Group, Simon Fraser University